Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/140650
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAso Pérez, Ester-
dc.contributor.authorSànchez, Àlex (Sànchez Pla)-
dc.contributor.authorVegas Lozano, Esteban-
dc.contributor.authorMaldonado, Rafael, 1961--
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)-
dc.date.accessioned2019-09-20T12:27:56Z-
dc.date.available2019-09-20T12:27:56Z-
dc.date.issued2015-01-01-
dc.identifier.issn1387-2877-
dc.identifier.urihttp://hdl.handle.net/2445/140650-
dc.description.abstractSeveral recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Moreover, THC + CBD reduced learning impairment in AβPP/PS1 mice. A significant decrease in soluble Aβ42 peptide levels and a change in plaques composition were also observed in THC + CBD-treated AβPP/PS1 mice, suggesting a cannabinoid-induced reduction in the harmful effect of the most toxic form of the Aβ peptide. Among the mechanisms related with these positive cognitive effects, the anti-inflammatory properties of cannabinoids may also play a relevant role. Here we observed reduced astrogliosis, microgliosis, and inflammatory-related molecules in treated AβPP/PS1 mice, which were more marked after treatment with THC + CBD than with either THC or CBD. Moreover, other cannabinoid-induced effects were uncovered by a genome-wide gene expression study. Thus, we have identified the redox protein thioredoxin 2 and the signaling protein Wnt16 as significant substrates for the THC + CBD-induced effects in our AD model. In summary, the present findings show that the combination of THC and CBD exhibits a better therapeutic profile than each cannabis component alone and support the consideration of a cannabis-based medicine as potential therapy against AD.-
dc.format.extent15 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherIOS Press-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.3233/JAD-141014-
dc.relation.ispartofJournal of Alzheimer's Disease, 2015, vol. 43, num. 3, p. 977-991-
dc.relation.urihttps://doi.org/10.3233/JAD-141014-
dc.rights(c) Aso, Ester et al., 2015-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationMalaltia d'Alzheimer-
dc.subject.classificationPèptids-
dc.subject.classificationCervell-
dc.subject.classificationEfectes secundaris dels medicaments-
dc.subject.classificationMarihuana-
dc.subject.classificationFarmacologia-
dc.subject.classificationPlaquetes sanguínies-
dc.subject.classificationMetabolisme-
dc.subject.otherAlzheimer's disease-
dc.subject.otherPeptides-
dc.subject.otherBrain-
dc.subject.otherDrug side effects-
dc.subject.otherMarijuana-
dc.subject.otherPharmacology-
dc.subject.otherBlood platelets-
dc.subject.otherMetabolism-
dc.titleCannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec647690-
dc.date.updated2019-09-20T12:27:56Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid25125475-
Appears in Collections:Articles publicats en revistes (Genètica, Microbiologia i Estadística)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
647690.pdf1.38 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.